 Patients undergo leukapheresis. The resulting dendritic cells DC are pulsed with wild-type wt p53 peptides with or without T-helper Th peptides. Individual autologous vaccines are prepared for each patient. Patients who are HLA-A2-DR4-negative are randomized to 1 of 2 treatment arms arm I or arm II. Patients who are HLA-A2-DR4-positive are assigned to arm III. 